Literature DB >> 10445068

Nasopharyngeal symptoms and nasal continuous positive airway pressure therapy in obstructive sleep apnoea syndrome.

J Lojander1, P E Brander, K Ammälä.   

Abstract

Nasal problems are often reported during the treatment of obstructive sleep apnoea syndrome (OSAS) with nasal continuous positive airway pressure (nCPAP) and may jeopardize the use of nCPAP. This retrospective study evaluated the frequency of nasopharyngeal symptoms in OSAS patients before and during nCPAP treatment. A questionnaire was sent to all patients (n = 194) with OSAS for whom nCPAP had been prescribed during the years 1990-1995 at the authors' hospital, enquiring about nasopharyngeal symptoms both before and during treatment and nCPAP use. The study population consisted of the 151 patients [128 men and 23 women, median (range) age 54 (31-76) years and body-mass index 34 (17-54) kg/m2] who responded to the questionnaire. Seventy-one percent of patients were still using nCPAP after a median treatment duration of 30 months. The most commonly reported nasopharyngeal symptoms were nasal stuffiness, which was reported by 46% of patients before nCPAP and by 37% during nCPAP, dry nose (39% before and 46% during nCPAP), sneezing (36% and 35%) and rhinorrhoea (21% and 27%). The frequency of nasopharyngeal symptoms did not change with nCPAP treatment. The frequency of nasopharyngeal symptoms before and during nCPAP treatment was similar in those patients who discontinued the treatment (n = 44, 29%) compared with those who continued with nCPAP (n = 107, 71%). Skin problems caused by the mask (50%), airleak from mouth (44%), difficulty in exhaling (29%) and a sensation of suffocation (26%) were also problems associated with nCPAP treatment. Nasopharyngeal symptoms were common in patients with OSAS before nCPAP was started. There was no significant change in the frequency of these symptoms during nCPAP treatment. Nasopharyngeal symptoms did not seem to affect treatment continuation.

Entities:  

Mesh:

Year:  1999        PMID: 10445068     DOI: 10.1080/00016489950181062

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Chronic Rhinosinusitis Is an Independent Risk Factor for OSA in World Trade Center Responders.

Authors:  Jag Sunderram; Michael Weintraub; Kathleen Black; Shahnaz Alimokhtari; Akosua Twumasi; Haley Sanders; Iris Udasin; Denise Harrison; Nishay Chitkara; Rafael E de la Hoz; Shou-En Lu; David M Rapoport; Indu Ayappa
Journal:  Chest       Date:  2018-10-25       Impact factor: 9.410

2.  The supraglottic effect of a reduction in expiratory mask pressure during continuous positive airway pressure.

Authors:  Maria J Masdeu; Amit V Patel; Vijay Seelall; David M Rapoport; Indu Ayappa
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

Review 3.  Nasal function and CPAP use in patients with obstructive sleep apnoea: a systematic review.

Authors:  Marina Brimioulle; Konstantinos Chaidas
Journal:  Sleep Breath       Date:  2021-09-02       Impact factor: 2.655

4.  Correlates of a prescription for Bilevel positive airway pressure for treatment of obstructive sleep apnea among veterans.

Authors:  Skai W Schwartz; Julie Rosas; Michelle R Iannacone; Philip R Foulis; W McDowell Anderson
Journal:  J Clin Sleep Med       Date:  2013-04-15       Impact factor: 4.062

5.  Nasal breathing and continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA).

Authors:  Jan H Hollandt; Malte Mahlerwein
Journal:  Sleep Breath       Date:  2003-06       Impact factor: 2.816

6.  A prospective randomized study comparing two different degrees of mandibular advancement with a dental appliance in treatment of severe obstructive sleep apnea.

Authors:  Marie-Louise Walker-Engström; Ivar Ringqvist; Olle Vestling; Bo Wilhelmsson; Ake Tegelberg
Journal:  Sleep Breath       Date:  2003-09       Impact factor: 2.816

7.  Willingness score obtained after a short CPAP trial predicts CPAP use at 1 year.

Authors:  Hanna-Riikka Kreivi; Paula Maasilta; Adel Bachour
Journal:  Sleep Breath       Date:  2013-06-28       Impact factor: 2.816

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.